NEW YORK — Selux Diagnostics said on Wednesday that it has met the first milestone in its antimicrobial susceptibility test (AST) development contract with the Biomedical Advanced Research and Development Authority (BARDA), triggering an $11.4 million payment.

The Boston-based company said it will use the new funding to advance its Next-Generation Phenotyping (NGP) test — an automated, high-throughput AST designed to provide results within 12 to 24 hours — through clinical trials.